The global pharmaceutical industry experienced a 38% drop in new job postings related to cell & gene therapy in Q2 2023 compared with the previous quarter, according to GlobalData’s Job Analytics. This compares to a 21% increase versus Q2 2022. GlobalData’s Melanoma Cell and Gene Therapy Market report offers a detailed analysis of the melanoma cell and gene therapy market, including patient-based forecasts. It covers market drivers, unmet needs, and competitive landscape of the market. Buy the report here.
Notably, Management Occupations jobs accounted for a 29% share of the global pharmaceutical industry’s cell & gene therapy-related total new job postings in Q2 2023, down 54% over the prior quarter.
Management Occupations drive cell & gene therapy-related hiring activity
Management Occupations, with a share of 29%, emerged as the top cell & gene therapy-related job roles within the pharmaceutical industry in Q2 2023, with new job postings drop by 54% quarter-on-quarter. Life, Physical, and Social Science Occupations came in second with a share of 18% in Q2 2023, with new job postings dropping by 24% over the previous quarter.
The other prominent cell & gene therapy roles include Computer and Mathematical Occupations with a 7% share in Q2 2023, Business and Financial Operations Occupations with a 4% share of new job postings.
Top five companies in pharmaceutical industry accounted for 58% of hiring activity
The top companies, in terms of number of new job postings tracked by GlobalData, as of Q2 2023 were Bristol-Myers Squibb, Vertex Pharmaceuticals, Catalent, Johnson & Johnson, and Takeda Pharmaceutical. Together they accounted for a combined share of 58% of all cell & gene therapy-related new jobs in the pharmaceutical industry.
Bristol-Myers Squibb posted 1,668 cell & gene therapy-related new jobs in Q2 2023, Vertex Pharmaceuticals 136 jobs, Catalent 123 jobs, Johnson & Johnson 106 jobs, and Takeda Pharmaceutical 96 jobs, according to GlobalData’s Job Analytics.
Hiring activity was driven by the US with a 67.83% share of total new job postings, Q2 2023
The largest share of cell & gene therapy-related new job postings in the pharmaceutical industry in Q2 2023 was in the US with 67.83% followed by India (6.63%) and China (3.97%). The share represented by the US was ten percentage points lower than the 77.82% share it accounted for in Q1 2023.
For further understanding of GlobalData's Melanoma Cell and Gene Therapy Market Size and Trend Report and Forecast to 2031, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Jobs Analytics uses machine learning to uncover key insights from tracking daily job postings for thousands of companies globally. Proprietary analysis is used to group jobs into key thematic areas and granular sectors across the world’s largest industries. classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
Smarter leaders trust GlobalData
Premium Insights Melanoma Cell and Gene Therapy Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs and Forecast to 2031
Premium Insights
The gold standard of business intelligence.
